The gross profit for the fourth quarter was reported at $39.1 million, up from $26.3 million in the prior year, resulting in a gross margin of 79.5%, compared to 75.0% in the previous year. Non-GAAP gross profit also showed significant improvement, reaching $39.2 million. Despite the positive revenue growth, the company reported a net operating loss of $17.8 million, which is slightly higher than the $16.1 million loss reported in the same quarter last year. Non-GAAP net operating loss was $12.5 million, down from $13.5 million.
For the full year 2025, Heartflow reported total revenue of $176.0 million, a 40% increase year-over-year, with U.S. revenue at $160.6 million and international revenue at $15.4 million. The company’s total operating expenses for the year were $199.3 million, reflecting increased investments in personnel and technology. The net loss for the year was $116.8 million, a significant improvement from the $96.4 million loss in 2024.
Looking ahead, Heartflow provided guidance for 2026, projecting total revenue between $218 million and $222 million, which translates to approximately 24% to 26% growth year-over-year. The company also anticipates a non-GAAP gross margin of 80% to 81%. John Farquhar, President and CEO of Heartflow, expressed confidence in the company’s growth trajectory, highlighting the accelerating adoption of the Heartflow Platform and the successful execution of their commercial and clinical strategies. The company will host a conference call to discuss these results in detail, emphasizing their commitment to transforming cardiovascular care through innovative technology.
